Avalere Health
A London-registered, Bridgepoint-owned health consultancy and pharma marketing group with about 1,500 staff, shrinking revenue and roughly $867M of debt and shareholder loans on its books.
Group accounts to Mar 2025, Companies House- Revenue
- $397.9M year to Mar 2025, down 2%; fee income after pass-through costs fell 13% to $262.5M.
- Valuation
- Not disclosed Bridgepoint bought it with management in Mar 2020; no price or later valuation published.
- Debt
- $387M bank loans plus $480M of related party loan notes; net liabilities of $630M at Mar 2025.
- Watch
- Next accounts due Dec 31, 2026 the year to Mar 2026 will show whether the slide in fee income stopped.
- AI
- In-house tools plus partners a suite of proprietary AI and data tools launched Feb 2025; GenAI literature review work with Nested Knowledge.
- Liquidity
- Phantom shares, paid on a sale awards crystallise only when the majority owner sells the group; no tender offer found.
- Hiring
- 39 → 46 remote listings since Oct 10.
Paid by drug makers to plan, prove and sell their medicines.
Three units since Jan 2025: Advisory (market access, health economics, evidence and US policy), Medical (medical communications, publications, KOL work) and Marketing (brand, launch and patient campaigns). Clients are mostly pharma and biotech. Of $397.9M turnover, $135.4M was pass-through, mostly media. No unit split is published.
Group accounts to Mar 2025, Companies House- 1Policy, evidence and marketing under one roofFishawack bought Avalere, a Washington DC policy and market access consultancy with 200+ advisors, in 2022 to pair US access expertise with medical and marketing work.Avalere Health release, Jun 2022
- 2Deep ties with big pharmaIt reports preferred client status with many of the top 20 pharma companies; client relationships can last more than 20 years.Group accounts to Mar 2025, Companies House
- 3Built by acquisitionThe company counted 19 acquired agencies and consultancies since 2001 when it took the Avalere Health name in Oct 2023.Avalere Health release, Oct 17, 2023
- IQVIA$44.1Blisted, Oct 30 close
- Omnicom$22.2Blisted, Oct 30 close
Private values are the last reported round; they can be stale. Listed values are market value. Bars start at zero.
Every round, and what its terms give away.
Avalere Health is private, so there is no share price. What its investors paid, and on what terms, is the closest thing to one.
- $398M
- annual revenue, as of Mar 31
- −2%
- growth, as reported
- 1,477
- employees, as reported
Operating loss $47.0M; net loss $146.0M; adjusted EBITDA $31.8M (prior year $47.3M).
Group accounts to Mar 2025, Companies House- Mar 31Related party loan notes$40MLed by Related parties (Bridgepoint funds hold most loan notes)Issued during the year to Mar 2025 at 12 to 14% interest, repayable Dec 2030. Interest accrual stopped from Jun 1, 2025.Group accounts to Mar 2025, Companies House
- Mar 31Bank facilities extended$387MLed by Third party lenders (not named)USD and GBP acquisition loans, maturity extended to Mar 2029, at 6.5% over SOFR or SONIA. A GBP 30M revolver, undrawn, runs to Sep 2028.Group accounts to Mar 2025, Companies House
- Jun 7Acquisition of Avalere (Bridgepoint-backed)Led by BridgepointBought from Inovalon; price not disclosed. Inovalon later returned $15M of the price.Avalere Health release, Jun 2022
- Mar 31Bridgepoint buyoutLed by Bridgepoint Europe VI, with managementBought from LDC, owner since Jan 2017. Fishawack then had about 850 staff and 14 offices. Price not disclosed.Group accounts to Mar 2025, Companies House
- Has the value of the business been written down?No priced round to compare, but the group impaired $61.5M of intangible assets in the year to Mar 2024 and $9.3M more in the year to Mar 2025.Group accounts to Mar 2025, Companies HouseFlag
- Time since the last equity dealBridgepoint bought in Mar 2020, about 5.5 years ago. Recent money came as shareholder loan notes ($40M in the year to Mar 2025), not new equity from outside.Group accounts to Mar 2025, Companies HouseFlag
- Unusual terms or heavy debt?Yes. $387M bank debt at 6.5% over benchmark, plus loan notes and priority shares at 12 to 14%. Interest paid and accrued was $103.2M against $31.8M adjusted EBITDA.Group accounts to Mar 2025, Companies HouseFlag
- New outside backer or insiders?Insiders. Of loan notes and priority shares, $298.4M was owed to Bridgepoint funds and $36.8M to current and former managers, before interest.Group accounts to Mar 2025, Companies HouseFlag
- Can staff sell shares?Not before an exit. Employee awards are cash-settled phantom shares that crystallise on a sale by the majority shareholder. No tender offer found.Group accounts to Mar 2025, Companies HouseFlag
- Layoffs in the last 12 months?No announced cut found since Nov 2025. Average staff fell from 1,639 to 1,477 in the year to Mar 2025, and the accounts cite restructuring and severance costs.Group accounts to Mar 2025, Companies HouseOpen
Clear: checked, nothing found. Flag: found, with the source. Open: could not be checked.
Avalere Health's revenue, year by year.
- Omnicom$0.21M
- IQVIA$0.19M
Lenders are owed $387M and shareholders $480M in loan notes, against $16.2M of cash. The shareholder notes stopped accruing interest from Jun 2025, which eases the paper loss but not the bank debt.
What the record says, and what we think it means.
The fact is the source's. The read, in italics, is ours.
- 01Watch
Fee income fell 13%.
Group accounts to Mar 2025, Companies HouseFee income after pass-through costs dropped to $262.5M from $303.3M in the year to Mar 2025; adjusted EBITDA fell to $31.8M from $47.3M.
The company blamed frozen client spend, the Inflation Reduction Act and FDA changes. The next accounts, due by Dec 31, 2026, will show if it recovered.
- 02Watch
Interest costs exceed earnings.
Group accounts to Mar 2025, Companies HouseInterest and similar charges were $103.2M against adjusted EBITDA of $31.8M; net loss was $146.0M; net liabilities $630.0M.
Much is non-cash shareholder interest, but bank interest alone ($49.2M) tops EBITDA.
- 03Watch
Five clients make up almost half of fee income.
Group accounts to Mar 2025, Companies HouseThe top five clients were 48% of net fee income in the year to Mar 2025.
Losing one big pharma account would hurt.
- 04Neutral
New CEO, new chair, finance chief off the board.
Companies House filings, checked Nov 3, 2026Amar Urhekar replaced Jon Koch as CEO in Jan 2025; Michael Davy of Bridgepoint became chair. CFO John Gransee left the board in Feb 2026, and a Bridgepoint director was swapped in Jul 2026.
Heavy turnover at the top, typical of an owner preparing a turnaround or a sale.
- 05Good
Opened in Japan.
Avalere Health release, May 11, 2026Launched a Tokyo office with advisory, medical and marketing services in May 2026, led by Junji Yokokawa.
Growth spending despite the debt load.
- 06Good
No mandated return to office.
Careers page, checked Nov 3, 2026Its careers page says there is no mandated return to the office; on Nov 3, 2026, 45 of 58 Lever postings were tagged remote.
Remote is policy, not a perk. Tokyo, Manchester and London roles lean hybrid.
- 07Neutral
Headquartered in London, not Washington DC.
Companies House company page, checked Nov 3, 2026The parent, Avalere Health Topco Limited, is registered at 66 City Road, London. Washington DC is the base of the Avalere consultancy it bought in 2022.
The legal parent and owner are UK based.
Other is paid 4% under market. Marketing, 12% under.
We save every company's roles, pay by team and level, AI share and churn every day, so each month this page can say more. Sparklines use their own scale.
Can AI agents do business with Avalere Health?
We checked the agent payment programs, developer docs and site rules an AI assistant would meet.
Open to crawlers, no agent doorway. Open robots.txt, no llms.txt, no API or MCP; job board blocks AI bots.
Still Remote read- YesLets AI crawlers read its siterobots.txt allows all user agents and only disallows /style/. No AI bot is named.checked Nov 3, 2026
- Not foundAn llms.txt file for AI toolsavalerehealth.com/llms.txt returns the site's home page HTML, not a text file. Same on advisory.avalerehealth.com.checked Nov 3, 2026
- MixedCan assistants read its job openingsJobs are on Lever. Its public API lists 58 roles, but Lever's robots.txt blocks GPTBot, ClaudeBot, CCBot and other AI crawlers.checked Nov 3, 2026
- Not foundAn MCP server or public APINo MCP server, public API or AI marketplace listing found in its newsroom or site.Avalere Health newsroom, checked Nov 3, 2026
- AnnouncedAI tools for client workSays it launched a suite of proprietary AI and data tools in Feb 2025 under its SenseMaking approach; none is sold as a standalone product.Avalere Health release, Jun 13, 2025
Where Avalere Health puts AI to work.
- 1GenAI for evidence reviewsPartnered with Nested Knowledge in May 2024 to bring generative AI into systematic literature reviews, alongside its own in-house AI tools.Avalere Health release, May 21, 2024
- 2Build and buyIts CTO describes a build and buy digital strategy; the 2025 accounts cite increased use of AI and GenAI tools across services.Group accounts to Mar 2025, Companies House
More listings than on Sep 7, most of them in marketing.
The signals, and which way they push.
- HeadwindA heavy debt load.
Bank interest of $49.2M a year exceeds adjusted EBITDA of $31.8M.
- HeadwindPharma clients cut discretionary spend.
Fee income fell 13% as clients froze spend after IRA and FDA changes.
- TailwindStill hiring senior leaders.
A US marketing president (Dec 2025), an SVP policy (Dec 2025) and an SVP market access (Oct 2026).
- TailwindNew market in Japan.
Full-service Tokyo office opened May 2026.
Where Avalere Health ends up, if we had to bet.
Our calls, not facts. Each one is tied to something that already happened, so you can judge the reasoning.
- 1
By 2031 Avalere Health has a new owner, or its lenders take a larger say.
Likely 72%M&ABridgepoint has held it since 2020, a long hold for a buyout fund. Staff phantom shares only pay out on a sale, which aligns management with one.
Group accounts to Mar 2025, Companies House - 2
Avalere Health lists on a stock exchange by 2036.
Long shot 16%IPONo filing has been reported, and it carries net liabilities of $630M. A sale to a buyer or another fund looks the more common path.
Group accounts to Mar 2025, Companies House - 3
Fee income is back above its $303M peak by the year to Mar 2029.
Coin flip 50%RevenueThe directors' plan assumes growth and new markets such as Japan are opening. Fee income fell 13% in the latest year, so the climb is steep.
Group accounts to Mar 2025, Companies House - 4
AI drafts most first versions of literature reviews and medical content it bills for.
Likely 72%AIIt already uses GenAI for literature reviews with Nested Knowledge. The accounts expect GenAI to lower costs in medical communications.
Avalere Health release, May 21, 2024 - 5
It stays a top-20 US health agency as holding companies and IQVIA consolidate the field.
Coin flip 50%CompetitionIt ranked #19 in the 2025 MM+M Agency 100, down from #15 in 2023. Larger rivals have more capital to invest.
Avalere Health release, Jun 13, 2025
Read by the Still Remote research agent on November 3, 2026 from the sources linked on this page. Facts and scenarios only, not investment advice.